What were the key takeaways from Taysha Gene’s earnings call?

What were the key takeaways from Taysha Gene's earnings call?

Did Taysha Gene beat or miss consensus estimates last quarter?

What is Taysha Gene's gross profit margin?

What factors drove the changes in Taysha Gene's revenue and profit?

What is the market's earnings forecast for Taysha Gene next quarter?

What is the revenue and EPS growth rate for Taysha Gene year over year?

What is Taysha Gene's latest dividend and current dividend yield?

- **FDA Breakthrough Designation**: TATIA-102 granted Breakthrough Therapy status, expediting path to potential approval for Rett Syndrome.
- **Pivotal Trial On Track**: First patient dosing in REVEAL trial scheduled for Q3 2025, with 15-patient enrollment targeting 3-6 months.
- **Strong Financial Position**: $297.3 million cash runway supports operations into 2028, enabling late-stage development.
- **Commercial Expansion**: Appointed Chief Commercial Officer to prepare for potential launch, targeting 10,000-20,000 patients in key markets.

**【CEO Summary Section】**
- Received FDA Breakthrough Therapy Designation for TATIA-102 in Rett Syndrome, recognizing its potential to address an unmet medical need.
- Finalized alignment with FDA on REVEAL pivotal trial protocol and statistical analysis plan, with enrollment of first patient scheduled for Q3 2025.
- Regained full global rights to TATIA-102 following expiration of Astellas option agreement.
- Appointed David McNinch as Chief Commercial Officer to support late-stage development and potential commercialization.

**【CFO Financial Commentary】**
- Q3 2025 R&D expenses: $25.7 million (vs. $14.9 million in Q3 2024), driven by BLA-enabling manufacturing and clinical trial activities.
- G&A expenses: $8.3 million (vs. $7.9 million in Q3 2024), due to debt issuance costs.
- Net loss: $32.7 million (vs. $25.5 million in Q3 2024), with $297.3 million cash runway supporting operations into 2028.

**【Q&A Key Highlights】**
- **Enrollment Expectations**: First patient dosing in pivotal trial scheduled for Q3 2025; potential enrollment of all 15 patients within 3-6 months due to high demand and site readiness.
- **FDA Alignment**: FDA confirmed no outstanding statistical or clinical queries, supporting use of 33% response rate threshold (5/15 patients) for interim analysis.
- **Younger Cohort Strategy**: Planning to initiate safety-focused trial for 2-5 year olds in mid-2026, with dose adjusted for brain volume to ensure safety.
- **Commercial Readiness**: Building infrastructure to support potential BLA submission, with focus on 10,000-20,000 US/EU/UK patients with Rett Syndrome.

Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

TSHA

TSHA fundamentals

You can ask Aime